Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 34Prostatic Neoplasms, Castration-Resistant 3Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostate Cancer Metastatic Disease 1Prostate Adenocarcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoadjuvant Therapy 1Metastatic Hormone-sensitive Prostate Cancer 1Melanoma 1Disease 1Castration-resistant Prostate Cancer 1Castrate Sensitive Prostate Cancer 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Anus Neoplasms 1

Interventions

Prednisone 3pembrolizumab 2Melphalan 2Cytarabine 2venetoclax 1ofatumumab 1obinutuzumab 1ioflupane 1imetelstat 1ibrutinib 1gossypol acetic acid 1gilteritinib 1fluorocholine 1fluciclovine F-18 1deltacortene 1daratumumab 1aflibercept 1abiraterone 1Temozolomide 1Self-Management 1Quality of Life 1Professional Autonomy 1Paclitaxel 1Oncolytic Virotherapy 1Octreotide 1Mitoxantrone 1Methylene Blue 1Lenalidomide 1Gemtuzumab 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Disease × abiraterone × Clear all
NCT07299292 2025-12-23

Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

SMED Clinical Research

Phase 2 Recruiting
60 enrolled
Genitourinary

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡